Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2006-07-04
2006-07-04
Saoud, Christine J. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S402000, C514S013800
Reexamination Certificate
active
07071300
ABSTRACT:
Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
REFERENCES:
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5342763 (1994-08-01), Swartz
patent: 5470828 (1995-11-01), Ballard et al.
patent: 2002/0165155 (2002-11-01), Schaffer et al.
patent: 0 294 021 (1988-04-01), None
patent: 0 369 943 (1989-11-01), None
patent: 0 375 438 (1989-12-01), None
patent: 742228 (1996-11-01), None
patent: WO 89/09792 (1988-06-01), None
patent: WO 89/08667 (1989-03-01), None
patent: WO 89/09268 (1989-03-01), None
patent: WO 91/03253 (1991-03-01), None
patent: WO 93/23067 (1993-11-01), None
patent: WO 93/23071 (1993-11-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 99/38011 (1999-07-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 01/25790 (2001-04-01), None
patent: WO 01/72771 (2001-10-01), None
Vajdos et al., “Crystal Structure of Human Insulin-Like Growth Factor-1: Detergent Binding Inhibits Binding Protein Interactions.”Biochemistry40:11022-11029 (2001).
Bach and Rechler., “Insulin-Like Growth Factor Binding Proteins.”Diabetes Reviews. 3(1):38-61 (1995).
Ballard et al., “Does IGF-I Ever Act Through the Insulin Receptor?”The Insulin-Like Growth Factors and Their Regulatory Proteins., Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).
Bar et al., “Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I.”Endocrinology, 127(6):3243-3245 (1990).
Baserga., “The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?”Cancer Research55:249-252 (Jan. 1995).
Baxter., “The Somatomedins: Insulin-Like Growth Factors.”Advances in Clinical Chemistry. 25:49-115 (1986).
Bayne et al., “Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 263:6233-6239 (1988).
Bayne et al., “The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor.”J. Bio. Chem. 264(19):11004-11008 (1988).
Bayne et al., “The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type I Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 265(26):15648-15652 (Sep. 15, 1990).
Binoux, M., “Recent Data on Somatomedins (Insulin-Like Growth Factors).”Annales d'Endocrinologie(English Abstract Included) 41:157-192 (1980).
Blundell et al., “Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding.”Proc. Natl. Acad. Sci. USA75(1):180-184 (Jan. 1978).
Blundell et al., “Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors.”Federation Proc. 42:2592-2597 (1983).
Buckbinder et al., “Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53.”Nature. 377:646-649 (Oct. 1995).
Cascieri et al., “Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor.”Biochemistry27(9):3229-3233 (May 3, 1988).
Cascieri et al., “Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors.”J. Bio. Chem. 264:2199-2202 (1989).
Clemmons and Van Wyk., “Somatomedin: Physiological Control and Effects on Cell Proliferation.”Handbook Exp. Pharmacol. 57:161-208 (1981).
Clemmons et al., “Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity.”J. Bio. Chem. 265(21):12210-12216 (1990).
Clemmons et al., “The Role of Insulin-Like Growth Factor Binding Proteins in Modifying IGF Actions.”Anal. NY Acad. Sci. USA692:10-21 (1993).
Cohen and Ellwein., “Cell Proliferation in Carcinogenesis.”Science. 249:1007-1011 (Aug. 1990).
Cohen and Ellwein., “Genetic Errors, Cell Proliferation, and Carcinogenesis.”Cancer Research. 51:6493-6505 (Dec. 1991).
Cohen et al., “Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease.”J. Endocrinology. 142:407-415 (1994).
Cohen et al., “Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells.”J. Clin. Endocrin.&Metab. 73:401-407 (1991).
Cohen et al., “The IGF Axis in the Prostate.”Horm.&Metab. Res. 26:81-84 (1994).
Cooke et al., “Solution Structure of Human Insulin-Like Growth Factor 1: A Nuclear Magnetic Resonance and Restrained Molecular Dynamics Study”Biochemistry30:5484-5491 (1991).
Culig et al., “Androgen Receptor Activation in Prostatic Tumor Cell Lines by Insulin-Like Growth Factor-I, Keratinocyte Growth Factor, and Epidermal Growth Factor.”Cancer Research. 54:5474-5478 (1994).
Cullen et al., “Insulin-Like Growth Factor Receptor Expression and Function in Human Breast Cancer.”Cancer Research. 50:48-53 (1990).
Daughaday and Rotwein., “Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations.”Endocrin. Rev. 10(1):68-91 (1989).
De Wolf et al., “Solution Structure of a Mini IGF-1.”Protein Sci. 5:2193-2202 (1996).
Dubaquie and Lowman, “Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3”Biochemistry38(20):6386-6396 (1999).
Feyen et al., “Recombinant Human [Cys281] Insulin-Like Growth Factor-Binding Protein 2 Inhibits Both Basal and Insulin-Like Growth Factor I-Stimulated Proliferation and Collagen Synthesis in Fetal Rat Calvariae.”J Bio. Chem, 266:19469-19474 (1991).
Figueroa et al., “Recombinant Insulin-Like Growth Factor Binding Protein-1 Inhibits IGF-I, Serum, and Estrogen-Dependent Growth of MCF-7 Human Breast Cancer Cells.”J. Cell Phys.157:229-236 (1993).
Garrett et al., “Crystal Structure of the First Three Domains of the Type-1 Insulin-Like Growth Factor Receptor.”Nature.394(6691):395-399 (Jul. 23, 1998).
Hasegawa et al., “The Free Form of Insulin-Like Growth Factor I Increases in Circulation During Normal Human Pregnancy.”J. Clin. Endocrinol. Metabol.80:3284-3286 (1995).
Hizuka et al., “Measurement of Free Form of Insulin-Like Growth Factor I in Human Plasma.”Growth Regulation.1:51-55 (1991).
Horney et al., “Elevated Glucose Increases Mesangial Cell Sensitivity to Insulin-Like Growth Factor I.”Am. J. Physiol.274:F1045-F1053 (1998).
Hsing et al., “Regulation of Apoptosis Induced by Transforming Growth Factor-β1 in Nontumorigenic and Tumorigenic Rat Prostatic Epithelial Cell Lines.”Cancer Research.56:5146-5149 (1996).
Humbel., “Insulin-Like Growth Factors I and II.”European Journal of Biochemistry.190:445-462 (1990).
Huynh et al., “Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-Like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells.”J. Bio. Chem.271(2):1016-1021 (1996).
“Insulin-Like Growth Factors and Cancer.”R&D Systems—Cytokine Bulletinpp. 1-2 (Fall Issue 2000).
Iwamura et al., “Insulin-Like Growth Factor I: Action and Receptor Characterization in Human Prostate Cancer Cell Lines.”Prostate.22:243-252 (1993).
Jones and Clemmons., “Insulin-Like Growth F
Deshayes Kurt D.
Lowman Henry B.
Schaffer Michelle L.
Sidhu Sachdev S.
Dreger Ginger R.
Genentech Inc.
Hasak Janet E.
Heller Ehrman LLP
Saoud Christine J.
LandOfFree
IGF antagonist peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IGF antagonist peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF antagonist peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3531767